Tower Research Capital LLC TRC Has $88,000 Position in AtriCure, Inc. (NASDAQ:ATRC)

Tower Research Capital LLC TRC boosted its position in AtriCure, Inc. (NASDAQ:ATRC) by 232.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 2,871 shares of the medical device company’s stock after buying an additional 2,008 shares during the quarter. Tower Research Capital LLC TRC’s holdings in AtriCure were worth $88,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ATRC. Heck Capital Advisors LLC acquired a new stake in shares of AtriCure in the 4th quarter valued at approximately $60,000. Venturi Wealth Management LLC raised its position in AtriCure by 1,337.6% during the fourth quarter. Venturi Wealth Management LLC now owns 2,257 shares of the medical device company’s stock worth $69,000 after acquiring an additional 2,100 shares in the last quarter. KBC Group NV lifted its stake in AtriCure by 65.3% in the fourth quarter. KBC Group NV now owns 2,360 shares of the medical device company’s stock valued at $72,000 after acquiring an additional 932 shares during the last quarter. R Squared Ltd bought a new position in shares of AtriCure in the 4th quarter valued at about $89,000. Finally, AlphaQuest LLC increased its stake in shares of AtriCure by 855.1% during the 4th quarter. AlphaQuest LLC now owns 5,062 shares of the medical device company’s stock worth $155,000 after purchasing an additional 4,532 shares during the last quarter. 99.11% of the stock is owned by institutional investors.

AtriCure Stock Performance

Shares of ATRC stock opened at $30.99 on Friday. The company has a quick ratio of 2.62, a current ratio of 3.65 and a debt-to-equity ratio of 0.13. The company has a market cap of $1.53 billion, a price-to-earnings ratio of -32.62 and a beta of 1.57. The firm has a 50 day moving average of $32.71 and a 200-day moving average of $34.74. AtriCure, Inc. has a 52 week low of $18.94 and a 52 week high of $43.11.

AtriCure (NASDAQ:ATRC) last announced its quarterly earnings data on Tuesday, April 29th. The medical device company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.11. AtriCure had a negative return on equity of 6.80% and a negative net margin of 9.61%. The firm had revenue of $123.62 million during the quarter, compared to analysts’ expectations of $122.92 million. During the same quarter last year, the firm posted ($0.28) earnings per share. The company’s revenue for the quarter was up 13.5% compared to the same quarter last year. On average, equities analysts forecast that AtriCure, Inc. will post -0.6 earnings per share for the current year.

Insider Buying and Selling at AtriCure

In other news, Director Karen Prange sold 6,100 shares of AtriCure stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $38.12, for a total transaction of $232,532.00. Following the completion of the transaction, the director now directly owns 17,828 shares in the company, valued at $679,603.36. This trade represents a 25.49 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 3.50% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities analysts recently commented on ATRC shares. Stifel Nicolaus lifted their price target on AtriCure from $36.00 to $48.00 and gave the stock a “buy” rating in a report on Thursday, February 13th. Piper Sandler boosted their target price on AtriCure from $40.00 to $50.00 and gave the stock an “overweight” rating in a report on Thursday, February 13th. UBS Group cut their price target on AtriCure from $60.00 to $58.00 and set a “buy” rating for the company in a report on Wednesday, April 30th. Oppenheimer upped their price objective on shares of AtriCure from $36.00 to $45.00 and gave the company an “outperform” rating in a report on Thursday, February 13th. Finally, Canaccord Genuity Group cut their target price on shares of AtriCure from $66.00 to $52.00 and set a “buy” rating for the company in a research note on Friday, March 28th. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, AtriCure presently has a consensus rating of “Moderate Buy” and a consensus price target of $50.67.

AtriCure Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.